Roche is the recipient of the new approval, getting the go-ahead from the US regulator for its PATHWAY HER2 (4B5) test to ...

Five Oceans Advisors raised its position in AstraZeneca PLC (NASDAQ:AZN – Free Report) by 11.9% in the fourth quarter, according to the company in its most recent disclosure with the Securities and ...

Crews Bank & Trust purchased a new position in AstraZeneca PLC (NASDAQ:AZN – Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange ...

AstraZeneca has revealed plans to set up a ... with highly-anticipated new HER2 drug Enhertu (trastuzumab deruxtecan) almost doubling to $76 million in the quarter, with potential new indications ...